Positive recommendation IDMC to Zepsyre® to continue Phase III trial

(Pharmamar) PharmaMar has announced today that the Independent Data Monitoring Committee has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre® (lurbinectedin, PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without any changes.

Positive recommendation IDMC to Zepsyre® to continue Phase III trial small-cell lung cancer

Related Posts

Agriculture accelerated human genome evolution to capture energy from starchy foods

Samples from bottled water, tap water and household-treated tap water in San Francisco Bay Area indicate that all sources may have potential health risks, largely from trihalomethanes

Both cats and dogs often enjoy playing fetch with their owners

PCORI offers up to $100 million for new research promoting healthy children and youth

POPULAR NEWS

NYU Abu Dhabi researchers identify unique survival strategies adopted by fish in the world’s warmest waters

Stem cells from diabetic patients coaxed to become insulin-secreting cells

UPR-induced ovarian cancer cell fusion: a mechanism favoring drug resistance?

Children’s Brain Tumor Network hosts 2024 CBTN Summit to transform scientific research and patient care

About

Follow us

Recent News

A new, updated account of poroid fungi in North America

Few anti-immigration users dominate most of UK-based anti-immigration content on Twitter with rapid spread and high polarization

Agriculture accelerated human genome evolution to capture energy from starchy foods

Welcome Back!

Retrieve your password